Epigenetic Reader Domain Inhibitors

Brd

BRPF1

BRPF2

BRPF3

BRD2

BRD3

BRD4

BRDT

CECR2

BD1

BD2

BRD7

BRD9

BET

BAZ

Epigenetic Reader Domain Inhibitors, Modulators, Degraders, Controls & Ligands

Product Name	Brd	BRPF1	BRPF2	BRPF3	BRD2	BRD3	BRD4	BRDT	CECR2	BD1	BD2	BRD7	BRD9	BET	BAZ	Purity
(+)-JQ-1							BRD4(BD1BD2)									99.91%
4-Chloro-N-methylpicolinamide															BAZ2A, Kd: >500 μM	99.89%
dBET6														BET		99.92%
ARV-771					BRD2(1), Kd: 34 nM BRD2(2), Kd: 4.7 nM	BRD3(1), Kd: 8.3 nM BRD3(2), Kd: 7.6 nM	BRD4(1), Kd: 9.6 nM BRD4(2), Kd: 7.6 nM									99.87%
dBET1							BRD4, EC₅₀: 430 nM									99.24%
JQ-1 carboxylic acid					BRD2	BRD3	BRD4							BET		99.69%
FHD-609													BRD9			98.95%
Pelabresib							BRD4-BD1, IC₅₀: 39 nM									99.95%
ABBV-744					BRD2 (BD2), IC₅₀: 8 nM	BRD3 (BD2), IC₅₀: 13 nM	BRD4 (BD2), IC₅₀: 4 nM BRD4 (BD2), Kd: 3 nM	BRDT (BD2), IC₅₀: 18 nM								99.97%
Mivebresib							BRD4									99.29%
BI-7273													BRD9			99.75%
GNE-987							BRD4 (BD1), IC₅₀: 4.7 nM BRD4 (BD2), IC₅₀: 4.4 nM									99.98%
GSK778					BRD2 BD1, IC₅₀: 75 nM	BRD3 BD1, IC₅₀: 41 nM	BRD4 BD1, IC₅₀: 41 nM	BRDT BD1, IC₅₀: 143 nM								99.14%
ZXH-3-26							BRD4, DC₅₀: 5 nM (5 hours of treatment)									99.53%
BAY-299		BRPF1 BD, IC₅₀: 3150 nM	BRPF2 BD, IC₅₀: 67 nM	BRPF3 BD, IC₅₀: 5550 nM												99.40%
XMD8-92							BRD4, Kd: 190 nM									99.48%
CPI-637							BRD4 BD1, IC₅₀: 11 μM									99.94%
VZ185												BRD7, DC₅₀: 4.5 nM	BRD9, DC₅₀: 1.8 nM			99.95%
A1874							BRD4									99.77%
FKBP12 PROTAC dTAG-7							BRD4									99.47%
BBC0403					BRD2 (BD2), Kd: 7.64 μM BRD2 (BD1), Kd: 41.37 μM											98.78%
BI-9564												BRD7, IC₅₀: 3.4 μM BRD7, Kd: 239 nM	BRD9, IC₅₀: 75 nM BRD9, Kd: 14 nM			98.96%
GSK046					BRD2 BD2, IC₅₀: 264 nM	BRD3 BD2, IC₅₀: 98 nM	BRD4 BD2, IC₅₀: 49 nM	BRDT BD2, IC₅₀: 214 nM								99.70%
AR/BRD4 RIPTAC-1							BRD4									98.65%
GNE-207							BRD4(1), IC₅₀: 3.1 μM									99.94%
I-BET762 carboxylic acid							BRD4, pIC₅₀: 5.1									99.55%
QCA570							BRD4 BD1, IC₅₀: 10 nM									99.30%
dBRD9													BRD9			99.75%
dBET57							BRD4 (BD1), DC₅₀: 500 nM									99.94%
NVS-CECR2-1							BRD4, IC₅₀: >37 μM		CECR2, IC₅₀: 47 nM CECR2, Kd: 80 nM			BRD7, IC₅₀: 5.5 μM	BRD9, IC₅₀: 2.3 μM			99.40%
GSK8814							BRD4 BD1, pIC₅₀: 4.6									99.80%
SIM1					BRD2, IC₅₀: 1.1 nM BRD2, Kd: 186 nM											99.47%
TP-472												BRD7, Kd: 0.34 μM	BRD9, Kd: 33 nM			99.54%
BRD7-IN-2												BRD7, IC₅₀: 5.4 μM	BRD9, IC₅₀: >300 μM			99.29%
TMX1					BRD2	BRD3	BRD4 BD2									99.57%
IBG3					BRD2, DC₅₀: 8.6 pM		BRD4, DC₅₀: 6.7 pM									98.53%
GSK973					BRD2 BD2, pIC₅₀: 7.5 BRD2 BD2, pKd: 8.3	BRD3 BD2, pIC₅₀: 7.8 BRD3 BD2, pKd: 8.5	BRD4 BD2, pIC₅₀: 7.8 BRD4 BD2, pKd: 8.7	BRDT BD2, pIC₅₀: 7.4 BRDT BD2, pKd: 8.3								99.97%
MS645							BRD4(BD1BD2), Ki: 18.4 nM									98.0%
SF2523							BRD4 (BD1), IC₅₀: 241 nM									99.34%
GSK1324726A							BRD4 BD2									99.92%
IBG1							BRD4, DC₅₀: 0.15 nM									99.88%
BETd-260					BRD2, IC₅₀: 30-100 pM	BRD3, IC₅₀: 30-100 pM	BRD4, IC₅₀: <30 pM									99.68%
ZL0580							BRD4 (BD1)									99.42%
PROTAC BRD4 Degrader-5-CO-PEG3-N3							BRD4									99.73%
MMH2							BRD4									98.95%
LT052		BRPF1b, IC₅₀: 567.5 nM				BRD3 BD1, IC₅₀: 246.3 nM	BRD4 BD1, IC₅₀: 87.7 nM	BRDT BD1, IC₅₀: 357.1 nM								98.02%
HLDA-221							BRD4 (BD1)									99.24%
(S)-JQ-35					BRD2	BRD3	BRD4	BRDT								99.46%
BRD4 degrader-1							BRD4									99.85%
dBRD 9-A													BRD9			99.50%
PLK1/BRD4-IN-5							BRD4, IC₅₀: 60.8 nM									98.80%
L-Moses	Brd, Kd: 126 nM															99.97%
BET-IN-31							BRD4									99.85%
HJB97					BRD2 BD1, Ki: 0.9±0.2 nM BRD2 BD2, Ki: 0.27±0.09 nM BRD2 BD1, IC₅₀: 3.1±0.7 nM BRD2 BD2, IC₅₀: 3.9±0.5 nM	BRD3 BD1, Ki: 0.18±0.01 nM BRD3 BD2, Ki: 0.21±0.03 nM BRD3 BD1, IC₅₀: 6.6±0.2 nM BRD3 BD2, IC₅₀: 1.9±0.4 nM	BRD4 BD1, Ki: 0.5±0.2 nM BRD4 BD1, IC₅₀: 7.0±0.6 nM BRD4 BD2, Ki: 1.0±0.1 nM BRD4 BD2, IC₅₀: 7.0±0.1 nM									98.05%
KB02-JQ1							BRD4									99.10%
iBRD4-BD1							BRD4									98.77%
BRD4 degrader-3							BRD4 BD1, IC₅₀: 15.5 nM BRD4 BD2, IC₅₀: 12.3 nM									99.43%
MZP-54							BRD4 BD2, Kd: 4 nM									98.03%
RVX-297					BRD2 (BD1), IC₅₀: 3.76 μM BRD2 (BD2), IC₅₀: 0.08 μM	BRD3 (BD1), IC₅₀: 2.34 μM BRD3 (BD2), IC₅₀: 0.05 μM	BRD4 (BD1), IC₅₀: 1.16 μM BRD4 (BD2), IC₅₀: 0.02 μM	BRDT (BD1), IC₅₀: 2.69 μM
JQ1-TCO							BRD4									99.95%
MMH1							BRD4									99.83%
JQ-1-Azidopropylamine							BRD4									99.5700%
PROTAC BRD9 Degrader-1							BRD4, IC₅₀: 3.78 μM						BRD9, IC₅₀: 13.5 nM			99.16%
BRD4/NAMPT-IN-1							BRD4(BD1BD2), IC₅₀: 58 nM BRD4 (BD1), IC₅₀: 12 nM BRD4 (BD2), IC₅₀: 41 nM									99.45%
SRX3177							BRD4 (BD1), IC₅₀: 33 nM									99.33%
GSK8573													BRD9, Kd: 1.04 μM			99.53%
TD-428							BRD4, DC₅₀: 0.32 nM									98.81%
PROTAC BRD4 Degrader-1							BRD4 (BD1), IC₅₀: 41.8 nM									99.31%
ZEN-2759							BRD4 (BD2), IC₅₀: 0.08 μM BRD4 (BD1), IC₅₀: 0.23 μM BRD4(BD1BD2), IC₅₀: 0.28 μM									99.51%
GSK9311		BRPF1, pIC₅₀: 6.0	BRPF2, pIC₅₀: 4.3													99.33%
FL-411							BRD4(1), IC₅₀: 0.43 μM									99.05%
GAL-02-221							BRD4									99.87%
GS-626510					BRD2, Kd: 0.59-2.5 nM	BRD3, Kd: 0.65-0.66 nM	BRD4, Kd: 1.3-3.2 nM			BD1, IC₅₀: 83 nM	BD2, IC₅₀: 78 nM					99.46%
CF53					BRD2 (BD1), Kd: 1.1 nM BRD2 (BD2), Kd: 0.6 nM	BRD3 (BD1), Kd: 0.52 nM BRD3 (BD2), Kd: 0.49 nM	BRD4 (BD1), IC₅₀: 2 nM BRD4 (BD2), Kd: 0.8 nM BRD4 (BD1), Ki: <1 nM BRD4 (BD1), Kd: 2.2 nM	BRDT (BD1), Kd: 2 nM BRDT (BD2), Kd: 1 nM	CECR2, Kd: 570 nM							99.81%
PROTAC BRD9 Degrader-7													BRD9, DC₅₀: 1.02 nM			99.29%
(Z)-JQ1-TCO							BRD4									99.12%
CW-3308													BRD9, IC₅₀: 5 nM			99.43%
MS402					BRD2-BD1, Ki: 83 nM BRD2-BD2, Ki: 240 nM	BRD3-BD1, Ki: 110 nM BRD3-BD2, Ki: 200 nM	BRD4-BD1, Ki: 77 nM BRD4-BD2, Ki: 718 nM									98.36%
SNIPER(BRD)-1							BRD4									99.68%
CBP/p300-IN-8							BRD4, IC₅₀: 1-1000 μM									98.03%
BRD4/CK2-IN-1							BRD4, IC₅₀: 180 nM									98.21%
BET bromodomain inhibitor 1					BRD2(2), Kd: 1.3 nM	BRD3(2), Kd: 1.0 nM	BRD4, IC₅₀: 2.6 nM BRD4(1), Kd: 3.0 nM BRD4(2), Kd: 1.6 nM	BRDT(2), Kd: 2.1 nM								99.67%
BRD4 Inhibitor-10							BRD4-BD1, IC₅₀: 8 nM									99.52%
UMB298							BRD4, IC₅₀: 5193 nM									99.28%
GNE-375													BRD9, IC₅₀: 5 nM			99.93%
BRD4 Inhibitor-20					BRD2 (BD1), IC₅₀: 24 nM BRD2 (BD2), IC₅₀: 18 nM		BRD4 BD1, IC₅₀: 19 nM BRD4 BD2, IC₅₀: 28 nM									99.24%
PROTAC BRD4 Degrader-2							BRD4 BD1, IC₅₀: 14.2 nM									98.30%
OARV-771					BRD2, DC₅₀: 1 nM	BRD3, DC₅₀: 4 nM	BRD4, DC₅₀: 6 nM									98.77%
Y06036							BRD4(1), Kd: 82 nM									98.57%
ODM-207							BRD4, IC₅₀: ≤ 1 μM									99.58%
TP-238 hydrochloride									CECR2, IC₅₀: 30 nM CECR2, Kd: 10 nM CECR2, pIC₅₀: 7.5				BRD9, pIC₅₀: 5.9			≥99.0%
PROTAC BRD4-binding moiety 1							BRD4									99.10%
PROTAC BET-binding moiety 2							BRD4									99.77%
XD14					BRD2, Kd: 170 nM	BRD3, Kd: 380 nM	BRD4, Kd: 160 nM
YM458							BRD4, IC₅₀: 34 nM									99.16%
I-BET787							BRD4 BD1, pIC₅₀: 7.1 BRD4 BD2, pIC₅₀: 5.9									99.88%
BRD9 ligand-6													BRD9
PLK1/BRD4-IN-3							BRD4 BD1, IC₅₀: 0.059 μM	BRDT BD1, IC₅₀: 0.245 μM								98.55%
GNE-987 GSH linker-2							BRD4									99.48%
I-BET567					BRD2, pIC₅₀: 7.2		BRD4 (BD1), pIC₅₀: 6.9									99.49%
NI-42		BRPF1, IC₅₀: 7.9 nM BRPF1, Kd: 40 nM	BRPF2, IC₅₀: 48 nM BRPF2, Kd: 210 nM	BRPF3, IC₅₀: 260 nM BRPF3, Kd: 940 nM			BRD4 (BD1), IC₅₀: 4500 nM					BRD7, IC₅₀: 82 nM	BRD9, IC₅₀: 310 nM BRD9, Kd: 1130 nM			99.53%
Desmethyl-QCA276							BRD4									99.16%
PLK1-IN-6							BRD4, IC₅₀: 156.3 nM
TRIM24/BRPF1-IN-2		BRPF1, IC₅₀: 1.16 μM														98.74%
cis-MZ 1							BRD4(BD1BD2)									99.8%
PNZ5							BRD4(1), Kd: 5.43 nM									99.61%
TAT-PiET-PROTAC							BRD4									98.04%
OXFBD02							BRD4(1), IC₅₀: 382 nM									98.04%
L-Moses dihydrochloride	Brd, Kd: 126 nM															99.38%
ML 2-14							BRD4									99.43%
Y06137							BRD4(1), Kd: 81 nM									99.90%
PROTAC BRD4 Degrader linker conjugate-1							BRD4									98.98%
XY221						BRD3 BD2, Ki: 70.98 nM	BRD4 BD1, IC₅₀: 3869 nM BRD4 BD2, IC₅₀: 5.8 nM
ET-JQ1-OH							BRD4
TrimTAC1							BRD4
BRD4 ligand 6							BRD4
BRD4 Inhibitor-24							BRD4									99.27%
CFT-2718							BRD4									99.87%
iBRD4-BD1 diTFA							BRD4									99.52%
ZEN-3219							BRD4 (BD1), IC₅₀: 0.48 μM BRD4 (BD2), IC₅₀: 0.16 μM BRD4(BD1BD2), IC₅₀: 0.47 μM									99.75%
(2S,3R)-LP99													BRD9, Kd: 99 nM			99.4%
ZEN-3862							BRD4 (BD1), IC₅₀: 0.16 μM BRD4 (BD2), IC₅₀: 0.13 μM									98.86%
PCIP-1														BET
Bromodomain inhibitor-8	Brd															98.02%
OXFBD04							BRD4, IC₅₀: 166 nM									98.99%
BRD4-BD1/2-IN-3										BD1, IC₅₀: 16.27 μM	BD2, IC₅₀: 0.41 nM					99.52%
L134							BRD4, DC₅₀: 7.36 nM									99.37%
BRD4 Inhibitor-13							BRD4									99.08%
PLK1/BRD4-IN-2							BRD4 ([1])									98.92%
XYD270													BRD9
AMX-883													BRD9
BET-IN-6					BRD2		BRD4
BRD7-IN-1 free base												BRD7	BRD9
GSK040											BD2, pIC₅₀: 8.3
GSK9311 hydrochloride		BRPF1, pIC₅₀: 6.0	BRPF2, pIC₅₀: 4.3
BRD4 Inhibitor-18							BRD4, IC₅₀: 110 nM
BET-IN-2							BRD4 BD1, IC₅₀: 52 nM
BY27					BRD2 BD2, Ki: 3.1 nM BRD2 BD1, Ki: 95.5 nM BRD2 BD2, Kd: 1.2 nM BRD2 BD1, Kd: 45 nM	BRD3 BD2, Ki: 5.3 nM BRD3 BD1, Ki: 77.9 nM BRD3 BD2, Kd: 2.6 nM BRD3 BD1, Kd: 12 nM	BRD4 BD2, Ki: 7.3 nM BRD4 BD1, Ki: 80 nM BRD4 BD2, Kd: 3.5 nM BRD4 BD1, Kd: 26 nM	BRDT BD2, Kd: 3 nM BRDT BD1, Kd: 64 nM
PROTAC BRD4 Degrader-45							BRD4, DC₅₀: 43 nM
XYD224													BRD9, DC₅₀: 7.3 nM
JQ1-S(GlcNAc)Cq							BRD4(BD1BD2)
PROTAC BRD4 Degrader-36							BRD4
BRD9 Degrader-4													BRD9
(S)-JQ-35-Boc							BRD4
Ad-JQ1							BRD4
CZL-149							BRD4 BD1, IC₅₀: 13 nM (AlphaScreen Assay) BRD4 BD2, IC₅₀: 78 nM (AlphaScreen Assay) BRD4 BD1, IC₅₀: 2 nM (HTRF Assay) BRD4 BD2, IC₅₀: 22 nM (HTRF Assay)
PROTAC BRD4 Degrader-44							BRD4
PROTAC FLT3/JAK2/BRD4 Degrader-1							BRD4, DC₅₀: 1.17 nM
BRD4-BD1-IN-1							BRD4 BD1, IC₅₀: 38.20 μM
PROTAC BRD4 Degrader-26							BRD4
BRD4 Inhibitor-31										BD1, Ki: 0.234 μM	BD2, Ki: 0.295 μM
PROTAC BRD4 Degrader-17							BRD4 (BD1), IC₅₀: 29.54 ± 2. nM BRD4 (BD2), IC₅₀: 3.82 ± 0.0 nM
PROTAC BRD3 degrader-1						BRD3
ZZ7-23-022													BRD9
GSK785					BRD2		BRD4							BET
JQ-1 (carboxylic acid)-amine-PEG8-cyanogen					BRD2	BRD3	BRD4
BRD4 degrader-6							BRD4, DC₅₀: <0.1 μM
BET-IN-30					BRD2	BRD3	BRD4
SJH1-51B							BRD4
PROTAC BRD2/BRD4 degrader-1					BRD2		BRD4
BRD9 ligand-11													BRD9
PROTAC BRD4 Degrader-33							BRD4
PROTAC BRD4 Degrader-21							BRD4, IC₅₀: 59 nM
BRD-SF2							BRD4
GXH-II-052							BRD4-1, Kd: 28 nM BRD4-2, Kd: 9.1 nM BRD4-T, Kd: 4.8 nM	BRDT-1, Kd: 0.6 nM BRDT-2, Kd: 8.4 nM BRDT-T, Kd: 2.6 nM
PI3Kδ/BET-IN-1							BRD4 (BD1), IC₅₀: 19 nM
KB-0118					BRD2 BD1, Kd: 36.7 μM BRD2 BD2, Kd: 74.3 μM		BRD4 BD1, Kd: 47.4 μM BRD4 BD2, Kd: 41.7 μM
SDR-04										BD1
PROTAC CBP/p300/BRD4 Degrader-1							BRD4, DC₅₀: 8.8 pM BRD4 BD1, IC₅₀: 44.6 nM BRD4 BD2, IC₅₀: 13.1 nM
PARP1/BRD4-IN-1							BRD4, IC₅₀: 202 nM
NC-III-49-1							BRD4-1, Kd: 0.095 nM BRD4-2, Kd: 0.032 nM BRD4-T, Kd: 0.29 nM	BRDT-1, Kd: 0.089 nM BRDT-2, Kd: 5.5 nM BRDT-T, Kd: 0.058 nM
ZEN-3411							BRD4 (BD1), IC₅₀: 0.05 μM BRD4 (BD2), IC₅₀: 0.05 μM BRD4(BD1BD2), IC₅₀: 0.06 μM
Mivebresib-alkyne														BET
SJ46421					BRD2 BD2, Kd: 2090 nM	BRD3 BD2, Kd: 987 nM	BRD4 BD2, Kd: 1020 nM
TAT-PiET							BRD4
BRD4 Inhibitor-15							BRD4(1), IC₅₀: 18 ± 1.1 nM
PROTAC BRD4 ligand-4							BRD4
PROTAC BRD4 Degrader-46					BRD2	BRD3	BRD4
BRD9 Degrader-2													BRD9, DC₅₀: <1.25 nM
RAJQ14					BRD2	BRD3	BRD4
KBD-1							BRD4
BRD4-IN-41							BRD4, : 34
BRD4 degrader-7							BRD4, DC₅₀: 489 nM
MrTAC-8							BRD4
PROTAC BRD4 Degrader-42							BRD4, DC₅₀: 1.11 μM
BRD9 ligand-14													BRD9
BETi-211														BET
BET-IN-26										BD1, IC₅₀: 0.0055 μM	BD2, IC₅₀: 9.0 μM
BET-IN-13					BRD2 BD1, IC₅₀: 79.3 nM BRD2 BD2, IC₅₀: 27.5 nM	BRD3 BD1, IC₅₀: 45.6 nM BRD3 BD2, IC₅₀: 18.9 nM	BRD4 BD1, IC₅₀: 57.4 nM BRD4 BD2, IC₅₀: 44.4 nM	BRDT BD1, IC₅₀: 87.0 nM BRDT BD2, IC₅₀: 43.4 nM
SJ44236							BRD4, DC₅₀: 127 pM
EBET-1593														BET
BRD4 degrader-2							BRD4
PROTAC BRD4 Degrader-38							BRD4, DC₅₀: 86 (BRD4-S nM BRD4, DC₅₀: 106 (BRD4- nM
BRD4 Inhibitor-40					BRD2 BD1, IC₅₀: 29.35 nM BRD2 BD2, IC₅₀: 302.35 nM		BRD4 BD1, IC₅₀: 16.1 nM BRD4 BD2, IC₅₀: 142.18 nM
NEP162							BRD4
PI3Kα-IN-28							BRD4
PROTAC BRD9 Degrader-11													BRD9
BET BD2-IN-1					BRD2 BD1, IC₅₀: 570 nM BRD2 BD2, IC₅₀: 5.9 nM	BRD3 BD1, IC₅₀: 465 nM BRD3 BD2, IC₅₀: 6.0 mM	BRD4 BD1, IC₅₀: 524 nM BRD4 BD2, IC₅₀: 1.6 nM	BRDT BD1, IC₅₀: 527 nM
HL403							BRD4, IC₅₀: 133 nM
BRD4-IN-11							BRD4 (BD1), IC₅₀: 26.35 nM BRD4 (BD2), IC₅₀: 72.81 nM
BRD3 ligand-1						BRD3
BRD4-IN-10							BRD4 (BD1), IC₅₀: 13.5 nM
PROTAC BRD4 Degrader-6							BRD4 BD1, IC₅₀: 2.7 μM
CDK4/6/BRD4-IN-1										BD1, IC₅₀: 146 nM	BD2, IC₅₀: 220 nM
PROTAC BET Degrader-17						BRD3, DC₅₀: 0.09 nM	BRD4, IC₅₀: 4.3 nM
KWZL-7f15							BRD4, IC₅₀: 56.41 nM
EBET-590														BET
BRD9 ligand-5													BRD9
PARP1/BRD4-IN-2							BRD4, IC₅₀: 238 nM
PROTAC BRD4 Degrader-37							BRD4
JQ1-FITC TFA							BRD4 BD1 BRD4 BD2
SB-284851-BT							BRD4-BD1, IC₅₀: 1.7 μM BRD4(1), IC₅₀: 3.7 μM	BRDT (1), IC₅₀: 18 μM
3-Methylcarbostyril							BRD4 BD1, pIC₅₀: 4.4
BET-IN-15							BRD4-BD1, IC₅₀: 0.64 nM BRD4-BD2, IC₅₀: 0.25 nM
SJ46420						BRD3
Bromodomain IN-2		BRPF1b, Kd: 130 nM					BRD4(1), Kd: 250 nM	BRDT (1), Kd: 240 nM				BRD7, Kd: 430 nM	BRD9, Kd: 67 nM
HDAC8/BRPF1-IN-1		hBRPF1, Ki: 67 nM
BRD4 Inhibitor-12							BRD4									99.34%
PROTAC BRD2 BD1 Degrader-1					BRD2 BD1
PROTAC BET Degrader-16					BRD2, DC₅₀: 6.44 nM	BRD3, DC₅₀: 7.93 nM	BRD4, DC₅₀: 0.31 nM
Naphthyridin-Me-dimethoxybenzene-COOH													BRD9
WNY0824					BRD2, IC₅₀: 402.5 nM	BRD3, IC₅₀: 150.7 nM	BRD4, IC₅₀: 103.9 nM	BRDT, IC₅₀: 311.9 nM
CBP/p300/BRD4 ligand-1							BRD4 (BD1) BRD4 (BD2)
JV8							BRD4
TMU454							BRD4
PROTAC BET Degrader-15					BRD2, DC₅₀: ＜0.10 nM	BRD3, DC₅₀: ＜0.01 nM	BRD4, DC₅₀: ＜0.01 nM
EA-89													BRD9
LCI40							BRD4 (BD2), IC₅₀: 1.88 μM BRD4 (BD1), IC₅₀: 0.19 μM
PROTAC BRD4 Degrader-31							BRD4, DC₅₀: 164 (4 h) nM BRD4, DC₅₀: 80 (80 h) nM
CK2-TN03							BRD4									98.02%
DW34							BRD4-BD1, : 0.14 μM
CN427							BRD4, Kd: 66 nM
JY-21							BRD4, DC₅₀: 3.797 μM
QA-68													BRD9
NB512							BRD4 BD1, EC₅₀: 0.36 μM BRD4 BD2, EC₅₀: 0.25 μM
SJ1461					BRD2 (BD1), IC₅₀: 1.6 nM BRD2 (BD2), IC₅₀: 0.1 nM		BRD4 (BD1), IC₅₀: 6.5 nM BRD4 (BD2), IC₅₀: 0.2 nM
CFT-743							BRD4, DC₅₀: 4.3 nM
BRD9 Degrader-3													BRD9, DC₅₀: 1.25-10 nM
PROTAC BRD4 Degrader-15							BRD4 BD1, IC₅₀: 7.2 nM BRD4 BD2, IC₅₀: 8.1 nM
BRD4 D1-IN-2							BRD4 BD1, IC₅₀: <0.092 μM
PROTAC BRD4 Degrader-29							BRD4, DC₅₀: 89.4 nM
PLX-4104							BRD4, DC₅₀: 2 nM
(S)-GNE-987							BRD4 (BD1), IC₅₀: 4 nM BRD4 (BD2), IC₅₀: 3.9 nM
PARP1/BRD4-IN-3					BRD2 BD2, IC₅₀: 6831 nM	BRD3, IC₅₀: 4792 nM	BRD4, IC₅₀: 1210 nM BRD4 BD1, IC₅₀: 204 nM BRD4 BD2, IC₅₀: 801 nM
BRD4-IN-5							BDI_K57-E168, Ki: 9.7 nM BDII_E352-M457, Ki: 16.1 nM
BRD4 Inhibitor-29							BRD4, IC₅₀: <100 nM nM
PROTAC BRD9 Degrader-8													BRD9, DC₅₀: 16 pM
IL-6/RIPK3-IN-1							BRD4, IC₅₀: 5.91 μM
PROTAC BRD4-DCAF1 degrader-1							BRD4
PROTAC BRD9-binding moiety 5													BRD9, IC₅₀: 4.2 μM
BRD4 ligand 14							BRD4
PROTAC BRD4 Degrader-43							BRD4
Penipanoid C							BRD4
BRD4-BD1-IN-2							BRD4-BD1, IC₅₀: 2.51 μM BRD4-BD2, IC₅₀: ＞50 μM
BRDT-IN-2								BRDT (BD1)
PROTAC BRD4 Degrader-3							BRD4
BRD4 Inhibitor-38							BRD4 BD1, IC₅₀: 3.64 μM BRD4 BD2, IC₅₀: 0.12 μM
BRD4-BD1-IN-3							BRD4 BD1
BRD4 ligand 8							BRD4
DCSM06-05	Brd, IC₅₀: 9 μM
AB3145							BRD4, DC₅₀: 120-140 pM
BRD4-IN-3							BRD4, IC₅₀: <0.5 μM
BRD4 ligand 15					BRD2	BRD3	BRD4	BRDT
NEP108							BRD4, DC₅₀: 3.8 μM
BRDT-IN-1								BRDT (BD1), IC₅₀: 19 nM BRDT-T, IC₅₀: 56 nM
PROTAC BRD9 Degrader-9													BRD9
BRD4 D1-IN-3							BRD4-BD1, IC₅₀: 39 nM BRD4-BD1, Ki: 2.4 nM
PROTAC BRD4 Degrader-40							BRD4
PROTAC BRD4 Degrader-41							BRD4, DC₅₀: 0.97 nM
PROTAC BRD4 Degrader-39							BRD4, DC₅₀: 24.66 nM
ZX079							BRD4, DC₅₀: 0.035 nM BRD4(1), IC₅₀: 0.9 μM BRD4(2), IC₅₀: 0.5 μM
Gal-ARV-771							BRD4
Bromodomain inhibitor-10							BRD4-1, Kd: 15 nM BRD4-2, Kd: 2500 nM
CZL-077					BRD2 (BD1), IC₅₀: 3.81 μM BRD2 (BD2), IC₅₀: >10 μM	BRD3 (BD1), IC₅₀: 5.54 μM BRD3 (BD2), IC₅₀: >10 μM	BRD4 BD1, IC₅₀: 6.45 μM BRD4 BD2, IC₅₀: >10 μM
BRD4 Inhibitor-27										BD1, IC₅₀: 9.6 μM	BD2, IC₅₀: 11.3 μM
JQ1-JX5							BRD4
BRD4-IN-12							BRD4, IC₅₀: 7.90 nM
TP-238									CECR2, pIC₅₀: 7.5 CECR2, IC₅₀: 30 nM CECR2, Kd: 10 nM				BRD9, pIC₅₀: 5.9
PROTAC BET Degrader-14							BRD4, DC₅₀: 130 nM BRD4, DC₅₀: 40 nM
Bromodomain inhibitor-9							BRD4-1, Kd: 12 nM BRD4-2, Kd: 5600 nM
SRX3212										BD1, IC₅₀: 3.7 nM	BD2, IC₅₀: 32 nM
PROTAC BRD9 Degrader-10													BRD9, IC₅₀: 2.97 μM
CBP/p300-IN-22							BRD4(1), Kd: 3.7 μM
BRD4 Inhibitor-25					BRD2 BD1, IC₅₀: 15.91 μM BRD2 BD1, Ki: 7.43 μM		BRD4-BD1, IC₅₀: 0.82 μM BRD4 (BD2), IC₅₀: 1.94 μM BRD4 BD1, Ki: 0.419 μM BRD4 BD2, Ki: 0.686 μM
(S)-BI 2536							BRD4, Ki: 54 nM
WWL0245							BRD4, IC₅₀: 1 nM
PROTAC BRD4 ligand-2							BRD4
PROTAC BRD4 Degrader-34							BRD4 BD2
TC AC 28					BRD2(1), Kd: 40 nM BRD2(2), EC₅₀: 800 nM
BRD9 ligand-12													BRD9
Hsp70TAC BRD4 Degrader-1							BRD4
BRD4/AKT-IN-1							BRD4, IC₅₀: 66.12 nM
BRD4 Inhibitor-19										BD1, IC₅₀: 55 nM
AB3067					BRD2, DC₅₀: 2.1 nM	BRD3, DC₅₀: 1.6 nM	BRD4, DC₅₀: 15 nM
BRD9 ligand-13													BRD9
BRD9 ligand-10													BRD9
XQ2							BRD4
GSK778 hydrochloride					BRD2 BD1, IC₅₀: 75 nM	BRD3 BD1, IC₅₀: 41 nM	BRD4-BD1, IC₅₀: 41 nM	BRDT BD1, IC₅₀: 143 nM
BRD4 ligand 13							BRD4
BI-7273 acid													BRD9
CDD-1147								BRDT BD2, IC₅₀: 94 nM
BRPF1B/TRIM24-IN-1		BRPF1, IC₅₀: 0.34 μM	BRPF2, IC₅₀: 1.75 μM
TW9							BRD4(1), Kd: 0.069 μM BRD4(2), Kd: 0.231 μM
CBP/p300-IN-24							BRD4 BD1, IC₅₀: 220 μM

Name
Email *

	Sorry, but the email address you supplied was invalid.